Travel grant Innovation Bridge 2025 India

Important results from the project

1. Secure financing for fundraise 2. Meet branded generics pharma 3. Negotiate Asia licensing rights

Expected long term effects

Prolevi Bio is a clinical-stage startup focused on drug delivery with its platform technology (with potential to expand to multiple molecules). As a first use case, we have developed a controlled release formulation of T3 (ProT3) for patients with hypothyroidism (a metabolic disease with 750 million patients worldwide, 80-90% women, underactive thyroid, first in its class).

Approach and implementation

Meetings were organized by the SIBC and a broad overview was seen in booming India economy. The activities were very well organized. Schedule was kept and other meetings were also organized outside planned activities by SIBC with key strategic players. Collaboration worked as intended.